NCT07289100 Novel Sensors and Artificial Intelligence for Detection of Acute Pulmonary Exacerbations in Cystic Fibrosis and Bronchiectasis
| NCT ID | NCT07289100 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Papworth Hospital NHS Foundation Trust |
| Condition | Cystic Fibrosis (CF) |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-09-30 |
| Primary Completion | 2026-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2025-09-30 with a primary completion date of 2026-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn about new sensors that measure changes in the body that happen during a chest infection, such as breathing rate and heart rate. This study will be with adults who have either cystic fibrosis or bronchiectasis who start treatment with intravenous antibiotics (usually for around 2 weeks). The main question it aims to answer is the change in sensor measure (such as heart rate) between the start and end of treatment for a chest infection. No follow up visits are required for this study.
Eligibility Criteria
Inclusion Criteria: * ≥ 18 years old * Diagnosis of CF based on genetic testing and /or sweat chloride levels or CT confirmed diagnosis of non-CF bronchiectasis * Under the care of Royal Papworth Hospital * Starting IV antibiotics for treatment of APE as defined by the Hill Criteria ² Exclusion Criteria: * Patients unable to provide written informed consent * Lung transplant recipients or on lung transplant waiting list * Use of long-term oxygen therapy (LTOT) or non-invasive ventilation to manage respiratory failure * Patients unwilling to consent to their link anonymised data from home monitoring being used for research * Considered unsuitable for home monitoring in the opinion of the investigator * Patients being admitted for elective antibiotic treatment (i.e. not being admitted for acute APE treatment)
Contact & Investigator
Andres Floto
PRINCIPAL INVESTIGATOR
University of Cambridge
Frequently Asked Questions
Who can join the NCT07289100 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cystic Fibrosis (CF). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07289100 currently recruiting?
Yes, NCT07289100 is actively recruiting participants. Contact the research team at lucy.gale1@nhs.net for enrollment information.
Where is the NCT07289100 trial being conducted?
This trial is being conducted at Cambridge, United Kingdom.
Who is sponsoring the NCT07289100 clinical trial?
NCT07289100 is sponsored by Papworth Hospital NHS Foundation Trust. The principal investigator is Andres Floto at University of Cambridge. The trial plans to enroll 50 participants.